

## Venous and Arterial Thrombosis Risk Testing

Policy Number: AHS – M2041 – Venous and Arterial Thrombosis Risk Testing	Prior Policy Name and Number, as applicable: <ul style="list-style-type: none"> <li>AHS – M2041 – Venous Thrombosis Risk Testing</li> </ul>
Policy Revision Date: 01/01/2025 Initial Policy Effective Date: 12/01/2024	

[POLICY DESCRIPTION](#) | 
 [RELATED POLICIES](#) | 
 [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | 
 [TABLE OF TERMINOLOGY](#) | 
 [SCIENTIFIC BACKGROUND](#) | 
 [GUIDELINES AND RECOMMENDATIONS](#) | 
 [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | 
 [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | 
 [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | 
 [REVISION HISTORY](#)

### I. Policy Description

A thrombosis, also known as a blood clot, occurs within blood vessels in the body. The two main types of thrombosis include venous thrombosis, which is when a vein is blocked due to a blood clot, and arterial thrombosis, which is when an artery is blocked due to a blood clot. Thrombophilias refer to hereditary and/or acquired abnormalities of hemostasis that predispose patients to thrombosis (Stevens et al., 2016). The most common presentations of venous thromboembolism (VTE) are deep vein thrombosis (DVT) and pulmonary embolism (PE) (Bartholomew, 2017).

Terms such as male and female are used when necessary to refer to sex assigned at birth.

### II. Related Policies

Policy Number	Policy Title
AHS-M2141	Testing of Homocysteine Metabolism-Related Conditions
AHS-M2180	Genetic Markers for Assessing Risk of Cardiovascular Disease

### III. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

- For individuals without recurrent venous thromboembolism (VTE) risk factors (e.g., surgery, prolonged immobilization, collagen vascular disease, malignancy, certain hematologic disorders), genetic testing for Factor V Leiden and prothrombin gene G20210A mutations and

plasma testing for protein C deficiency, protein S deficiency, and antithrombin III deficiency (see Note 1) **MEETS COVERAGE CRITERIA** in any of the following situations:

- a) For individuals less than 50 years of age who have experienced any deep venous thrombosis (DVT) or pulmonary embolism (PE).
  - b) For individuals who have experienced a DVT in unusual sites (e.g., hepatic, mesenteric, or cerebral veins).
  - c) For individuals who have experienced a DVT and who have a strong family history of thrombotic disease.
  - d) For individuals who are pregnant or taking oral contraceptives and who have experienced a DVT.
  - e) For first- and second-degree relatives (see Note 2) of individuals who experienced a DVT before 50 years of age.
  - f) For women under the age of 50 who smoke and who have suffered a myocardial infarction.
  - g) Before the administration of oral contraceptives, targeted testing of individuals with a personal or family history of DVT.
  - h) For pediatric individuals who have suffered from a pediatric arterial ischemic stroke.
- 2) For individuals with warfarin-induced skin necrosis or for infants who develop neonatal purpura fulminans, plasma testing for protein C deficiency and protein S deficiency (see Note 1) **MEETS COVERAGE CRITERIA**.
  - 3) For individuals with a first-degree relative (see Note 2) with a known Factor V Leiden or prothrombin gene G20210A mutation, genetic testing for the known familial mutation **MEETS COVERAGE CRITERIA** in any of the following situations:
    - a) For individuals who are considering the use of oral contraceptives.
    - b) For individuals who were assigned female at birth and who are considering hormone replacement therapy.
  - 4) For hypercoagulable evaluation or for “at risk” family members, *MTHFR* genetic testing **DOES NOT MEET COVERAGE CRITERIA**.
  - 5) For individuals with recurrent thrombotic events who are receiving a lifelong anticoagulation regimen, genetic testing for Factor V Leiden and prothrombin gene G20210A mutations **DOES NOT MEET COVERAGE CRITERIA**.
  - 6) Venous thrombosis risk testing for superficial venous thrombosis (including superficial thrombophlebitis and varicosities) **DOES NOT MEET COVERAGE CRITERIA**.
  - 7) For all situations, activated protein C (aPC) resistance assay **DOES NOT MEET COVERAGE CRITERIA**.

*The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.*

- 8) Genetic testing for inherited thrombophilia **DOES NOT MEET COVERAGE CRITERIA** for any of the following situations:
  - a) For the evaluation of recurrent fetal loss, placental abruption, preeclampsia, or fetal growth restriction.
  - b) For the evaluation of arterial thrombosis not attributable to paradoxical emboli.
  - c) As a routine screen for the general population.
  - d) As a routine screen for asymptomatic individuals considering oral contraceptive use or hormone replacement therapy.
  - e) As a routine screen for asymptomatic pregnant individuals.
  - f) For prenatal or preimplantation testing.
  - g) As a routine newborn screen.
- 9) Genetic testing for inherited thrombophilia more than once per lifetime **DOES NOT MEET COVERAGE CRITERIA.**
- 10) Testing for other genetic thrombophilia risk factors (e.g., factor V HR2 variant, prothrombin G1199A variant, factor VII R353Q variant, factor 13B V34L variant, PAI-1), as well as multi-gene panel testing **DOES NOT MEET COVERAGE CRITERIA.**
- 11) DVT risk testing as part of a pre-transplant evaluation test **DOES NOT MEET COVERAGE CRITERIA.**
- 12) To determine arterial thrombosis risk, genetic testing for Factor V Leiden mutation and prothrombin gene G20210A mutation **DOES NOT MEET COVERAGE CRITERIA.**

---

## NOTES:

**Note 1:** Plasma testing for protein C deficiency, protein S deficiency, and antithrombin III deficiency should be performed at least six weeks after the acute thrombotic event and while the patient is not taking anticoagulants. Assays for clotting inhibitors amount and function should be performed prior to any molecular testing.

**Note 2:** First-degree relatives include parents, full siblings, and children of the individual. Second-degree relatives include grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings of the individual.

## IV. Table of Terminology

Term	Definition
------	------------

ACC	American College of Cardiology
ACMG	American College of Medical Genetics and Genomics
ACOG	American College of Obstetricians and Gynecologists
ACR	American College of Radiology
AHA/ASA	American Heart Association/American Stroke Association
aPC	Activated protein C
APS	Antiphospholipid syndrome
ASCP	American Society for Clinical Pathology
ASH	American Society of Hematology
COC	Combined oral contraceptives
CTPA	Computed tomography pulmonary angiography
DVT	Deep vein thrombosis
EGAPP	Evaluation of genomic applications in practice and prevention
ESC	European Society of Cardiology
FVL	Factor V Leiden
HRT	Hormone replacement therapy
NAFT	The North American Thrombosis Forum
OC	Oral contraceptives
PE	Pulmonary embolism
PGM	Prothrombin 20210A gene mutation
SIGN	Scottish Intercollegiate Guidelines Network
SPESI	Simplified pulmonary embolism severity index
SVM	Society for Vascular Medicine
VQ	Ventilation perfusion
VTE	Venous thromboembolism
VUS	Variant of unknown significance

## V. Scientific Background

A thrombus is “an aggregate of coagulated blood within the vascular system or heart which contains platelets, fibrin, leukocytes, and red blood cells in varying amounts” (Herrmann, 2018). This aggregate of blood can be problematic as it may obstruct normal blood circulation throughout the body and even travel to peripheral areas. The primary manifestations of venous thromboembolisms (VTE) are deep vein thrombosis and pulmonary embolism. These conditions affect an estimated one million individuals in the United States annually (Bartholomew, 2017).

Thrombosis is widely theorized to develop due to Virchow’s Triad, which consists of abnormalities in blood flow, a vascular endothelial injury, and alterations in the blood constituents. Changes in any of these characteristics may cause the clot to form (Bauer & Lip, 2024). For example, sickle red blood cells may cause increased clumping or decreased adhesion to the vessel walls (Byrnes & Wolberg, 2017). There are two main types of thrombosis: venous

thrombosis (when a vein is blocked due to a blood clot) and arterial thrombosis (when an artery is blocked due to a blood clot).

A deep vein thrombosis (DVT) refers to a thrombus in a “deep” vein whereas a pulmonary embolism (PE) refers to an obstruction of the pulmonary artery (or one of its branches) by foreign material (Bauer, 2024a; Thompson, 2023). DVT of the lower extremities may cause symptoms, such as swelling or edema in the lower extremities, pain, and warmth in the affected area (Bauer, 2024a). This thrombus may travel to the lungs (becoming an embolus) and cause a PE. A PE has similar symptoms to DVT but may include pulmonary issues, such as shortness of breath. The risk factors for VTE, PE, and DVT are similar (Thompson, 2023). The two primary categories of risk factors for VTE are hereditary and acquired, and the genetic tendency toward VTE is referred to as inherited thrombophilia. Hereditary risk factors include genetic mutations such as Factor V Leiden (FVL) mutations. The five most common genetic risk factors for VTE are FVL mutations, prothrombin mutations, protein S defect, protein C defect, and antithrombin defect (Bauer & Lip, 2024). Approximately 50–60% of the variance in VTE incidence are attributed to genetic effects (Crous-Bou et al., 2016).

A modified activated partial thromboplastin time (aPTT) assay detects the anticoagulant activity of activated protein C (aPC). FVL mutations cause coagulation factor V to be unresponsive to aPC and initially, these changes were termed “aPC resistance” due to the reduced activity of aPC on a modified aPTT assay. A single nucleotide change (G1691A) results in a point mutation of glutamine to arginine at position 506. Approximately 99% of carriers of this mutation are heterozygous, and only 5% of these heterozygotes will experience a VTE in their lifetime. These mutations are often suspected in patients experiencing a VTE at a young age (under 50), a VTE in unusual areas such as a portal vein, or recurrent VTEs (Bauer, 2023a). Protein C may also be genetically deficient, but this mutation is only seen in 2-5% of individuals with a VTE (Bauer, 2024a). Protein S, a cofactor for the aPC control mechanism, and deficiencies in this protein may also confer additional risk for VTE (Bauer, 2024b).

The second most common inherited thrombophilia is the G20210A mutation of prothrombin. This mutation is a gain of function mutation where clotting activity is increased by creating more thrombin and fibrin. The overall prevalence of this mutation is about 2% (Bauer, 2023c). Genetic defects of antithrombin (an inhibitor of thrombin) may also occur, but the estimated prevalence of antithrombin defects is only a maximum of 0.2% (Bauer, 2023b).

Acquired risk factors or predisposing conditions for thrombosis include a prior thrombotic event, recent major surgery, presence of a central venous catheter, trauma, immobilization, malignancy, pregnancy, the use of oral contraceptives or heparin, myeloproliferative disorders, antiphospholipid syndrome (APS), and a number of other major medical illnesses (Bauer & Lip, 2024). Patients with acquired hypercoagulability have an increased risk of venous thrombosis, arterial thrombosis, or both; however, there is a low risk of recurrence, regardless of thrombophilia status (Connors, 2017). A rare complication of warfarin treatment, warfarin-induced skin necrosis is commonly due to protein C deficiency, with rare cases of protein S deficiency or PVL having been reported (Bauer & Lip, 2023).

Risk factors for arterial thrombosis are lesser known. The relationship between FVL and arterial thrombosis is controversial with studies reporting varying results; overall, FVL is not currently

considered a major risk factor for arterial thrombosis (Carroll & Piazza, 2018; Kujovich, 2011). Kujovich (2018) states that FVL testing should not be performed on persons with any type of arterial thrombosis including myocardial infarction and stroke in children or adults. It has also been reported that while inherited antithrombin, protein S and protein C deficiencies are important risk factors for venous thrombosis, “they have little or no effect on arterial thrombosis” (Previtali et al., 2011). Further, prothrombin gene mutation is not consistently shown to increase the risk of an arterial thromboembolism, and “There is no association of antithrombin deficiency with arterial thrombosis” (Carroll & Piazza, 2018).

It has been proposed that venous thrombosis risk testing may be beneficial as a pre-transplant evaluation test. However, no studies have been identified suggesting this. The North American Thrombosis Forum (NAFT) states that even though certain genetic conditions predispose a small proportion of the population to the development of blood clots, “few people with thrombophilias develop symptoms”; further, there is no cost-effective, safe or long-term method to prevent a blood clot from forming even if a genetic predisposition is identified (NATF, 2019).

Thrombotic events such as thrombophilia and stroke have become increasingly documented in hospitalized pediatric patients with underlying medical conditions such as prematurity, cancer, and congenital heart disease, but they are rarely identified in healthy children. Furthermore, in most cases of pediatric venous thromboembolism, there exist other underlying risk factors such as indwelling central venous catheter and inherited thrombophilia that are worthy of further investigation. The incidence of venous thromboembolisms is highest in neonates and infants, but there is a second peak recorded in adolescence, coinciding with the use of oral contraceptives. However, as in the case with adults, little to no evidence suggests that the use of venous thrombosis risk testing in children will affect the acute management of venous thromboembolisms. In a study including a total of 271 children with VTE, it was found that the relative frequencies of individually inherited thrombophilias were low—for example, the highest recorded frequency of IT disorders was of Factor V Leiden, occurring in only five to 10 percent of the samples. Moreover, a study of 52 children with thromboembolic events during the acute phase did not urge any changes to acute management, regardless of the result of the test (Raffini et al., 2023).

Venous thrombosis risk testing has also been entertained as a manner of combatting pediatric stroke, which can be characterized in a variety of ways, such as by age and by presentation. Arterial ischemic infarctions are the most common, comprising approximately 80% of all perinatal strokes, and this form of stroke can occur in up to one in 3500 of newborns. However, though it would seem reasonable for venous thrombosis risk testing to be employed here, recent prospective case-control studies suggest that routine thrombophilia testing is not warranted. The study showed that conditions associated with thrombophilia rarely coincided with arterial ischemic strokes, and these conditions included, but were not limited to, decreased levels of protein C, protein S, or prothrombin, and genotyping of factor V Leiden (FVL) and factor II (FII, prothrombin) G20210A. Of the 14 parameters examined, 12 showed no difference, including all common thrombophilias examined, with specific mention that FVL and FII were comparable to population norms (Curtis et al., 2017; Ferriero et al., 2019). Subsequent evaluation deemed thrombophilia evaluation in neonates as having limited clinical utility because “levels of protein C, protein S, antithrombin, and factor XI are normally decreased to 30% of adults levels, and



these levels only approach adult levels at various time points during childhood”. Therefore, the use of thrombophilia testing for these proteins may be misleading in the neonatal period, and MRIs instead should be used to diagnose the thrombosis (Ferriero et al., 2019). Moreover, studies focusing on the roles of thrombophilia, arteriopathy, and cardiac abnormalities in perinatal ischemic stroke find that these risk factors were at best unclear, weakening what predictive power they were believed to contain for even recurrent events after perinatal stroke and leading researchers to conclude that thrombophilia evaluation should rarely be considered in cases of perinatal stroke (Lehman et al., 2017).

While the initial aPTT assays used unaltered plasma (first-generation assays), some versions were neither sensitive nor specific for FVL. Modifications to this test resulted in second generation functional aPC resistance assays that correlate well with the presence of FVL. However, in rare cases, functional assays for aPC resistance can give misleading results (e.g., the presence of a lupus anticoagulant can cause falsely abnormal results in some assays; therapy with a direct thrombin inhibitor or oral factor Za inhibitor can cause falsely normal results). In addition, while FVL can be detected by genetic testing or a second-generation functional coagulation test for aPC resistance, individuals with a positive aPC resistance assay would still need to receive genetic testing to confirm a diagnosis (Bauer, 2023a). Due to difficulty with interpretation, a need for confirmatory genetic testing, and the overall declining cost of genetic testing, aPC resistance assays are performed infrequently. When performed, they are simply reported as positive, borderline, or negative (Middeldrop, 2023).

The term FVL paradox describes the different risk of DVT and PE in FVL carriers; there is data to suggest that FLV carriers are less likely to experience isolated PE (without DVT) than the general population (Bauer, 2023a). de Moerloose et al. (2000) studied the prevalence of FVL in people suspected of DVT and/or PE. The 99 participants with PE were categorized based on “those with PE but without DVT (n = 57) and those with PE and DVT (n = 42).” The odds ratio for the prevalence of FVL was higher (19.1%) in patients with DVT and PE than the odds ratio for the prevalence of FVL in patients with only PE (10.5%), suggesting that “patients with primary PE are less often affected by the factor V Leiden mutation.” In another study by (Mäkelburg et al., 2010), the relative risk of DVT in FVL carriers compared to non-carriers was 7.0, while the relative risk of PE in FVL carriers compared to non-carriers was 2.8.

### ***Analytical Validity***

Murphy and Sabath (2019) have compared the accuracy and reliability of two tests: a genotypic assay which identifies FVL mutations, and a phenotypic aPC resistance assay. Data from 1596 patients was analyzed; each patient had received both types of testing. The authors state that the phenotypic testing exhibited both high sensitivity and specificity compared to genotypic testing. “Phenotypic assays had close to total concordance with genotypic assays over 16 years of testing. Changing ordering practices could result in up to an 80% reduction in testing costs” (Murphy & Sabath, 2019).

A systematic review and meta-analysis by Chiasakul et al. (2019) researched the relationship between inherited thrombophilia and the risk of arterial ischemic stroke in adults. Inherited thrombophilias included FVL, protein C and S deficiency, antithrombin deficiency and prothrombin G20210A mutation. For this study, 11,916 stroke patients and 96,057 controls were

identified. The authors concluded that “Compared with controls, patients with arterial ischemic stroke were significantly more likely to have the following inherited thrombophilias: factor V Leiden (OR, 1.25; 95% CI, 1.08-1.44; I<sup>2</sup>=0%), prothrombin G20210A mutation (OR, 1.48; 95% CI, 1.22-1.80; I<sup>2</sup>=0%), protein C deficiency (OR, 2.13; 95% CI, 1.16-3.90; I<sup>2</sup>=0%), and protein S deficiency (OR, 2.26; 95% CI, 1.34-3.80; I<sup>2</sup>=8.8%)” (Chiasakul et al., 2019). Antithrombin deficiency did not reach statistical significance in this study. Hence, in this review, inherited thrombophilias were found to be associated with an increased risk of arterial ischemic stroke in adults.

In a systematic review, Ortega studied the predictive value of D-dimer testing for venous thrombosis diagnosis in unusual locations. 3378 patients from 23 articles with thrombosis in unusual sites, such as upper extremity deep vein thrombosis (DVT), cerebral vein thrombosis (CVT) and splanchnic vein thrombosis (SVT), were studied. 12 articles on CVT concluded that timing of D-dimer testing is important and patients with short duration of symptoms displayed higher D-dimer levels. Sensitivity and specificity in these patients ranged from 58% to 97% and from 77% to 97.5%, respectively. The authors conclude that “D-dimer testing should not be currently recommended for the diagnosis of thrombosis in unusual sites as a first line diagnostic tool. The development of algorithms combining biomarkers such as D-dimer and clinical decision tools could improve the diagnosis” (Ordieres-Ortega et al., 2020).

### ***Clinical Utility and Validity***

A D-dimer assay is a blood test that is used in clinical practice to assist in identifying if a patient has a DVT or PE; this test may also help patients experiencing unprovoked VTE to determine if anticoagulation treatment should continue or halt after initial treatment is complete (Linkins & Takach Lapner, 2017). A D-dimer assay may vary greatly based on the type of antibody used, the method of capture, calibration, and instrumentation. Currently, 30 different assays are available which use 20 different monoclonal antibodies; various studies have reported a broad sensitivity and specificity range for D-dimer assays from 69-97% and 43-99% respectively (Linkins & Takach Lapner, 2017). Hence, all D-dimer assays differ and need to be validated within the population of interest. Because of this, comparing study results is challenging.

Factor VIII is a blood clotting protein encoded by the F8 gene. A case report by Algahtani and Stuckey (2019) suggests that high factor VIII levels may also assist in risk factor determination for thrombosis or ischemic heart disease. “We conclude that high factor VIII levels are a risk factor for thrombosis, with a greater impact on venous than on arterial thrombosis. However, due to a lack of international consensus on methods for the laboratory testing of factor VIII levels in plasma, we would not currently recommend the measurement of factor VIII levels as part of routine thrombophilia screening” (Algahtani & Stuckey, 2019). This relationship has been shown previously as elevated levels of coagulation factor VIII:C were identified in a retrospective study of 584 first-degree relatives of 177 patients with high coagulation factor VIII:C levels; the researchers found that 40% of first degree relatives also had high VIII:C levels and were at an increased risk for VTE and arterial thrombosis when compared to other first-degree relatives with normal VIII:C levels (Bank et al., 2005).

Lee et al. (2017) performed whole exome sequencing on 64 patients with VTE to assess the types of mutations of inherited thrombophilias. Of these 64 patients, 39 of them were found to have a



pathogenic variant or variant of unknown significance (VUS). Further, eight were found to have a Factor V mutation (six with FVL and two with less common mutations), two were found to have a prothrombin G20210A mutation, six were found to have a protein S mutation, two were found to have a protein C mutation, and three were found to have an antithrombin mutation (Lee et al., 2017).

Segal et al. (2009) reviewed the utility of FVL and prothrombin G20210A testing. The authors reviewed 124 articles and concluded that although genetic testing for these two risk factors is very accurate (valid), the clinical utility is lacking due to lack of evidence demonstrating improvement in clinical outcomes (Segal et al., 2009).

Onda studied the clinical utility of a new diagnostic algorithm based on serum D-dimer levels for VTE after hepatectomy. A total of 742 patients who underwent hepatectomy were enrolled in the study and measured for serum D-dimer levels post-op. CT scan was performed for patients who had a D-dimer level of greater than 20 µg/mL. Based on D-dimer and CT scan, VTE was diagnosed in 26 patients and pulmonary embolism (PE) was diagnosed in 18 patients. Multivariate analysis also showed that a resected liver weight of more than 120 grams is a significant predictor of VTE. Overall, “patients who undergo hepatectomy are at high risk for VTE, especially when the resected liver weight is high. The proposed diagnostic algorithm based on serum D-dimer levels for VTE after hepatectomy can be useful for early diagnosis” (Onda et al., 2021).

## VI. Guidelines and Recommendations

### American Heart Association/American Stroke Association (AHA/ASA)

The AHA/ASA has issued a scientific statement for the management of stroke in neonates and children, wherein testing for thrombophilic abnormalities are discussed. The AHA/ASA admits that due to the lack of “an adequately powered study to detect the impact of genetic thrombophilia on recurrence risk in pediatric AIS [arterial ischemic stroke], definite recommendations about evaluation remain challenging”, but acknowledges that “laboratory testing outside of clinical studies may provide guidance for long-term management of the patient”. For cases of thrombophilia the AHA/ASA provides an algorithm for the “Targeted Evaluation of a Child With AIS for Rare Causes or Causes Requiring Additional Evaluation” that includes the examination of Factor VIII level, Lipoprotein(a), *MTHFR* mutation, and homocysteine levels, and it is suggested that “non-DNA testing may need to be repeated when the child is older to ensure that adult levels of proteins have been attained” and “measurement of proteins or homocysteine levels in the acute phase of stroke may not be accurate and should be repeated after the acute event”. Finally, for the evaluation of a child with AIS, it is believed that “A thrombophilia evaluation is helpful in every case of childhood stroke, especially if there is no identifiable cause, medical history of thrombosis, or a first-degree relative with thrombosis history” (Ferriero et al., 2019).

In 2021, the AHA released guidelines on stroke prevention. The AHA brushes on testing for hematologic traits in the context of secondary stroke prevention. “If in certain clinical scenarios (eg, paradoxical emboli caused by venous thrombosis or recurrent venous thrombosis) testing for thrombophilic states is considered, testing for protein C, protein S, or antithrombin levels should

be deferred or repeated at least 4 to 6 weeks (or up to 6 months for factor VIII609) after the acute stroke given that these protein levels may be altered during the acute stroke phase” (Kleindorfer et al., 2021).

### **American College of Medical Genetics and Genomics (ACMG)**

ACMG has released guidelines for laboratory testing of venous thromboembolism (VTE). This 2018 edition superseded the 2005 edition. The guidelines are as follows:

Testing for factor V Leiden and factor II c.\*97G>A (this mutation is also known as G20210A) is recommended in the following circumstances:

- A first unprovoked VTE, especially <50 years old
- VTE at unusual sites (such as hepatic portal, mesenteric, and cerebral veins)
- Recurrent VTE
- Personal history of VTE with (a) two or more family members with a history of VTE or (b) one first-degree relative with VTE at a young age
- Patients with low aPC resistance activity

Testing may be considered in the following circumstances:

- Females under the age of 50 who smoke tobacco and have a history of acute myocardial infarction
- Siblings of individuals known to be homozygous for factor V Leiden or factor II c.\*97G>A, because they have a one in four chance of being a homozygote
- Asymptomatic pregnant individual or individual contemplating pregnancy, with a first-degree relative with unprovoked VTE or VTE provoked by pregnancy or contraceptive use
- Pregnant individual or individual contemplating pregnancy or estrogen use who has a first-degree relative with a history of VTE and is a known carrier for factor V Leiden and/or factor II c.97\*G>A variant
- Pregnant individual or individual contemplating pregnancy with a previous non-estrogen-related VTE or VTE provoked by a minor risk factor, because knowledge of the factor V Leiden or factor II c.\*97G>A status may alter pregnancy related thrombophylaxis (Zhang et al., 2018).

The ACMG found several clinical scenarios requiring special considerations worth mentioning, involving different populations. One involved the testing of asymptomatic versus symptomatic individuals, in which they assert that “It is generally not recommended to test asymptomatic minors as VTE rarely occurs before young adulthood even in the homozygous state.” For prenatal testing and population screening, the ACMG suggests that “prenatal testing and population screening are not indicated due to the low penetrance of these variants, later age of onset, and lack of genotype-directed prophylaxis”. Lastly, in individuals considering taking estrogen-containing oral contraceptives (OC) or hormone replacement therapy (HRT), the ACMG indicates that “A family and personal history of thrombosis should be carefully evaluated for all women before initiating HRT and a positive history may warrant thrombophilia screening” (Zhang et al., 2018).

ACMG does not support testing for *MTHFR* variants in thrombophilia assessment due to the lack of correlation with negative pregnancy outcomes (Hickey et al., 2013). This statement was reaffirmed in 2020 (Bashford et al., 2020).

### **American Society of Hematology (ASH)**

The 2013 ASH recommends against testing “for thrombophilia in adult patients with venous thromboembolism (VTE) occurring in the setting of major transient risk factors (surgery, trauma or prolonged immobility)” (ASH, 2013).

In 2018, ASH released their guidelines for management of venous thromboembolism, which included the following recommendations (Lim et al., 2018). These guidelines were reviewed in 2022 by an ASH expert working group and agreed to “continue monitoring the supporting evidence rather than revise or retire these guidelines at this time.”

- *“Recommends* using a strategy starting with D-dimer for excluding PE in a population with low prevalence/PTP ( $\leq 5\%$ ), followed by ventilation-perfusion (VQ) scan or computed tomography pulmonary angiography (CTPA) for patients requiring additional testing.
- *Recommends against* using a positive D-dimer alone to diagnose PE, and against additional testing following negative CTPA or normal VQ scan in a population with low prevalence/PTP ( $\leq 5\%$ ).
- *Suggests* using a strategy starting with D-dimer for excluding PE in a population with intermediate prevalence/PTP ( $\sim 20\%$ ), followed by VQ scan or CTPA for patients requiring additional testing.
- *Recommends against* using a positive D-dimer alone to diagnose PE, and against additional testing following negative CTPA or normal VQ scan in a population with intermediate prevalence/PTP ( $\sim 20\%$ ).
- *Recommends against* using a positive D-dimer alone to diagnose PE, and against using D-dimer as a subsequent test following a negative CT scan in a population with high prevalence/PTP ( $\geq 50\%$ ).
- *Suggests* using a strategy starting with D-dimer for excluding recurrent PE in a population with unlikely PTP.
- *Recommends* using a strategy starting with D-dimer for excluding DVT in a population with low prevalence/PTP ( $\leq 10\%$ ), followed by proximal lower extremity ultrasound or whole-leg ultrasound for patients requiring additional testing.
- *Recommends against* using a positive D-dimer alone to diagnose DVT, and against additional testing following negative proximal or whole-leg ultrasound in a population with low prevalence/PTP ( $\leq 10\%$ ).
- *Recommends against* using a positive D-dimer alone to diagnose DVT in a population with intermediate prevalence/PTP ( $\sim 25\%$ ).
- *Recommends against* using a positive D-dimer alone to diagnose DVT in a population with high prevalence/PTP ( $\geq 50\%$ ).
- *Suggests* using a strategy starting with D-dimer for excluding recurrent DVT in a population with unlikely PTP.
- *Suggests* a strategy starting with D-dimer for excluding upper extremity DVT in a population with low prevalence/unlikely PTP ( $10\%$ ), followed by duplex ultrasound if D-

dimer is positive.

- *Recommends against* using a positive D-dimer alone to diagnose upper extremity DVT in a population with low prevalence/unlikely PTP (10%).
- *Suggests* a strategy of either D-dimer followed by duplex ultrasound/serial duplex ultrasound, or duplex ultrasound/serial duplex ultrasound alone for assessing patients suspected of having upper extremity DVT in a population with high prevalence/likely PTP (40%).
- *Recommends against* using a positive D-dimer alone to diagnose upper extremity DVT in a population with high prevalence/likely PTP (40%)” (Lim et al., 2018).

In 2020, the ASH released guidelines on management of venous thromboembolism. ASH suggest “against the routine use of prognostic scores, D-dimer testing, or venous ultrasound to guide the duration of anticoagulation” (Ortel et al., 2020).

In 2023, the ASH released guidelines thrombophilia testing for the management of venous thromboembolism. “The panel issued a strong recommendation against testing the general population before starting combined oral contraceptives (COCs) and conditional recommendations for thrombophilia testing in the following scenarios: (a) patients with VTE associated with nonsurgical major transient or hormonal risk factors; (b) patients with cerebral or splanchnic venous thrombosis, in settings where anticoagulation would otherwise be discontinued; (c) individuals with a family history of antithrombin, protein C, or protein S deficiency when considering thromboprophylaxis for minor provoking risk factors and for guidance to avoid COCs/hormone replacement therapy; (d) pregnant women with a family history of high-risk thrombophilia types; and (e) patients with cancer at low or intermediate risk of thrombosis and with a family history of VTE. For all other questions, the panel provided conditional recommendations against testing for thrombophilia.” The panel also listed the following 23 recommendations (Middeldorp et al., 2023):

- “For patients with unprovoked VTE who have completed primary short-term treatment, the ASH guideline panel suggests not to perform thrombophilia testing to guide the duration of anticoagulant treatment (conditional recommendation based on very low certainty in the evidence about effects).”
- “For patients with VTE provoked by surgery who have completed primary short-term treatment, the ASH guideline panel suggests not to perform thrombophilia testing to determine the duration of anticoagulant treatment (conditional recommendation based on very low certainty in the evidence about effects).”
- “For patients with VTE provoked by a nonsurgical major transient risk factor who have completed primary short-term treatment, the ASH guideline panel suggests testing for thrombophilia to guide anticoagulant treatment duration. The panel suggests indefinite anticoagulant treatment for patients with thrombophilia and stopping anticoagulant treatment for patients without thrombophilia (conditional recommendation based on very low certainty in the evidence about effects).”
- “For women with VTE provoked by pregnancy or postpartum who have completed primary treatment, the ASH guideline panel suggests thrombophilia testing to guide anticoagulant treatment duration. The panel suggests indefinite anticoagulant treatment for women with

thrombophilia and stopping anticoagulant treatment for women without thrombophilia (conditional recommendation based on very low certainty in the evidence about effects).”

- “For women with VTE associated with COCs who have completed primary short-term treatment, the ASH guideline panel suggests testing for thrombophilia to guide anticoagulant treatment duration. The panel suggests indefinite anticoagulant treatment for women with thrombophilia and stopping anticoagulant treatment for women without thrombophilia (conditional recommendation based on very low certainty in the evidence about effects).”
- “For patients with an unspecified type of VTE who have completed primary short-term treatment, the ASH guideline panel suggests not performing thrombophilia testing to guide anticoagulant treatment duration (conditional recommendation based on very low certainty in the evidence about effects).”
- “For patients with CVT who have completed primary treatment in a setting where anticoagulation would be discontinued, the ASH guideline panel suggests thrombophilia testing to guide anticoagulant treatment duration. The panel suggests indefinite anticoagulation for patients with thrombophilia (conditional recommendation based on very low certainty in the evidence about effects).”
- “For patients with CVT who have completed primary treatment in a setting where anticoagulation would be continued indefinitely, the ASH guideline panel suggests not to perform thrombophilia testing to guide anticoagulant treatment duration (conditional recommendation based on very low certainty in the evidence about effects).”
- “For patients with splanchnic venous thrombosis who have completed primary treatment in a setting where anticoagulation would be discontinued, the ASH guideline panel suggests thrombophilia testing to guide anticoagulant treatment duration. The panel suggests indefinite anticoagulation for patients with thrombophilia (conditional recommendation based on very low certainty in the evidence about effects).”
- “For patients with splanchnic venous thrombosis who have completed primary treatment in a setting where anticoagulation would be continued indefinitely, the ASH guideline panel suggests not performing thrombophilia testing to guide anticoagulant treatment duration (conditional recommendation based on very low certainty in the evidence about effects).”
- “For individuals with a family history of VTE and known FVL or PGM [prothrombin 20210A gene mutation] (low-risk thrombophilia) who have a minor provoking risk factor for VTE (eg, immobility or minor injury, illness, or infection), the ASH guideline panel suggests not testing for the known familial thrombophilia to guide thromboprophylaxis (conditional recommendation based on very low certainty in the evidence about effects). For individuals with a family history of VTE and known antithrombin, protein C, or protein S deficiency (high-risk thrombophilia) who have a minor provoking risk factor for VTE, the ASH guideline panel suggests testing for the known familial thrombophilia. The panel suggests thromboprophylaxis in individuals with thrombophilia and no thromboprophylaxis in individuals without thrombophilia (conditional recommendation based on very low certainty in the evidence about effects).”
- “For individuals with a family history of VTE and known FVL or PGM (low-risk thrombophilia) who have a minor provoking risk factor for VTE (eg, immobility or minor injury, illness, or infection), the ASH guideline panel suggests not testing for all hereditary



thrombophilias to guide thromboprophylaxis (conditional recommendation based on very low certainty in the evidence about effects). For individuals with a family history of VTE and known antithrombin, protein C, or protein S deficiency (high-risk thrombophilia) who have a minor provoking risk factor for VTE, the ASH guideline panel suggests testing for all hereditary thrombophilias (using a panel of tests). The panel suggests thromboprophylaxis in individuals with thrombophilia and no thromboprophylaxis for a minor provoking risk factor in individuals without thrombophilia (conditional recommendation based on very low certainty in the evidence about effects).”

- “For individuals with a family history of VTE and unknown thrombophilia status in the family who have a minor provoking risk factor for VTE (eg, immobility or minor injury, illness, or infection), the ASH guideline panel suggests not testing for all hereditary thrombophilias (using a panel of tests) to guide thromboprophylaxis (conditional recommendation based on very low certainty in the evidence about effects).”
- “For individuals with a family history of FVL or PGM (low-risk thrombophilia) but no family history of VTE who have a minor provoking risk factor for VTE (eg, immobility or minor injury, illness, or infection), the ASH guideline panel suggests not testing for the known thrombophilia to guide thromboprophylaxis (conditional recommendation based on very low certainty in the evidence about effects). For individuals with a first-degree family history of antithrombin, protein C, or protein S deficiency (high-risk thrombophilia) but no family history of VTE who have a minor provoking risk factor for VTE, the ASH guideline panel suggests testing for the known thrombophilia. The panel suggests thromboprophylaxis in individuals with thrombophilia and no thromboprophylaxis in individuals without thrombophilia (conditional recommendation based on very low certainty in the evidence about effects). For individuals with a second-degree family history of antithrombin, protein C, or protein S deficiency (high-risk thrombophilia) but no family history of VTE who have a minor provoking risk factor for VTE, the ASH guideline panel suggests either testing for the known thrombophilia or not testing for thrombophilia to guide the use of thromboprophylaxis (conditional recommendation based on very low certainty in the evidence about effects).”
- “For women from the general population who are considering using COCs, the ASH guideline panel recommends not performing thrombophilia testing to guide the use of COC (strong recommendation based on low certainty in the evidence about effects).”
- “For women from the general population who are considering using HRT, the ASH guideline panel suggests not performing thrombophilia testing to guide the use of HRT (conditional recommendation based on low certainty in the evidence about effects).”
- “For women with a family history of VTE and unknown thrombophilia status in the family who are considering using COCs, the ASH guideline panel suggests not testing for hereditary thrombophilia (using a panel of tests) to guide the use of COC (conditional recommendation based on very low certainty in the evidence about effects).”
- “For women with a family history of VTE and unknown thrombophilia in the family who are considering using HRT, the ASH guideline panel suggests not performing thrombophilia testing for any hereditary thrombophilia to guide the use of HRT (conditional recommendation based on very low certainty in the evidence about effects).”
- “For women with a family history of VTE and known FVL or PGM in the family (low-risk thrombophilia), the ASH guideline panel suggests not testing for the known familial



thrombophilia to guide the use of COC (conditional recommendation based on very low certainty in the evidence about effects). For women with a family history of VTE and known antithrombin, protein C, or protein S deficiency in the family (high-risk thrombophilia), the ASH guideline panel suggests testing for the known familial thrombophilia. The panel suggests avoidance of COCs for women with high-risk thrombophilia (conditional recommendation based on very low certainty in the evidence about effects).”

- “For women with a family history of VTE and known FVL or PGM in the family (low-risk thrombophilia), the ASH guideline panel suggests not testing for the known familial thrombophilia to guide the use of HRT (conditional recommendation based on very low certainty in the evidence about effects). For women with a family history of VTE and known antithrombin, protein C, or protein S deficiency in the family (high-risk thrombophilia), the ASH guideline panel suggests testing for the known familial thrombophilia. The panel suggests avoidance of HRT for women with high-risk thrombophilia (conditional recommendation based on very low certainty in the evidence about effects).”
- “For women with a family history of VTE and known homozygous FVL, a combination of FVL and PGM, or an antithrombin deficiency in the family, the ASH guideline panel suggests testing for the known familial thrombophilia. The panel suggests antepartum thromboprophylaxis for women with the same familial thrombophilia (ie, homozygous FVL, combination of FVL and PGM, or antithrombin deficiency) and no antepartum prophylaxis for women without the same familial thrombophilia (conditional recommendation based on very low certainty in the evidence about effects). For women with a family history of VTE and a known protein C or protein S deficiency in the family, the ASH guideline panel suggests either testing for the known familial thrombophilia or not testing for thrombophilia to guide antepartum prophylaxis (conditional recommendation based on very low certainty in the evidence about effects).”
- “For women with a first-degree family history of VTE and known homozygous FVL, a combination of FVL and PGM, antithrombin deficiency, protein C deficiency, or protein S deficiency in the family, the ASH guideline panel suggests testing for the known familial thrombophilia. The panel suggests postpartum thromboprophylaxis for women with the same familial thrombophilia (ie, homozygous FVL, combination of FVL and PGM, or antithrombin deficiency) and no postpartum prophylaxis for women without the same familial thrombophilia (conditional recommendation based on very low certainty in the evidence about effects). For women with a second-degree family history of VTE and a known combination of FVL and PGM, or antithrombin deficiency in the family, the ASH guideline panel suggests testing for the known familial thrombophilia. The panel suggests postpartum thromboprophylaxis for women with thrombophilia and no postpartum prophylaxis for women without thrombophilia (conditional recommendation based on very low certainty in the evidence about effects). For women with a second-degree family history of VTE and a known protein C or protein S deficiency in the family, the ASH guideline panel suggests either testing for the known familial thrombophilia or not testing for thrombophilia to guide postpartum thromboprophylaxis (conditional recommendation based on very low certainty in the evidence about effects).”
- “For ambulatory patients with cancer receiving systemic therapy who have a family history of VTE and are otherwise determined to be at low or intermediate risk for VTE, the ASH

guideline panel suggests testing for hereditary thrombophilia. The panel suggests ambulatory thromboprophylaxis for patients with thrombophilia and no thromboprophylaxis for patients without thrombophilia (conditional recommendation based on very low certainty in the evidence about effects).”

### **American College of Obstetricians and Gynecologists**

The 2013 ACOG clinical management guidelines recommend that screening for inherited thrombophilia “may be considered in the following clinical settings:

1. “A personal history of venous thromboembolism that was associated with a non-recurrent risk factor
2. A first degree relative (parent or sibling) with a history of high-risk thrombophilia” (ACOG, 2013).

The 2018 ACOG Practice Bulletin Summary Number 197 supersedes the above 2013 guidelines (Practice Bulletin Number 138). In this update, the ACOG makes the following recommendations regarding screening based on “limited or inconsistent scientific evidence”:

“Screening for inherited thrombophilias is not recommended for women with a history of fetal loss or adverse pregnancy outcomes including abruption, preeclampsia, or fetal growth restriction because there is insufficient clinical evidence that antepartum prophylaxis with unfractionated heparin or low molecular-weight heparin prevents recurrence in these patients.”

“Because of the lack of association between either heterozygosity or homozygosity for the *MTHFR* C677T polymorphism and any negative pregnancy outcomes, including any increased risk of VTE, screening with either *MTHFR* mutation analyses or fasting homocysteine levels is not recommended.”

The 2018 ACOG recommends the following screening guideline based on “consensus and expert opinion”:

“Among women with personal histories of VTE, recommended screening tests for inherited thrombophilias should include factor V Leiden mutation; prothrombin G20210A mutation; and antithrombin, protein S, and protein C deficiencies” (ACOG, 2018).

### **Evaluation of Genomic Applications in Practice and Prevention**

“The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found adequate evidence to recommend against *routine* testing for Factor V Leiden (FVL) and/or prothrombin 20210G>A (Gupta et al.) in the following circumstances: (1) adults with idiopathic venous thromboembolism (VTE). In such cases, longer term secondary prophylaxis to avoid recurrence offers similar benefits to patients with and without one or more of these mutations. (2) Asymptomatic adult family members of patients with VTE and an FVL or PT mutation, for the purpose of considering primary prophylactic anticoagulation. Potential benefits are unlikely to exceed potential harms. The evidence was insufficient to determine whether FVL/PT testing might have clinical utility in some circumstances, such as for identifying FVL homozygosity among asymptomatic family members of adults with idiopathic VTE or counseling patients about

the risks and benefits of antithrombotic therapy. The recommendations do not extend to patients with other risk factors for thrombosis, such as contraceptive use, as the evidence review that serves as the basis for the recommendations focused primarily on idiopathic VTE” (EGAPP, 2011).

### **The Anticoagulation Forum**

The Anticoagulation Forum published guidance in the Journal of Thrombosis and Thrombolysis on (Stevens et al., 2016):

- “Do not perform thrombophilia testing following an episode of provoked VTE. A positive thrombophilia evaluation is not a sufficient basis to offer extended anticoagulation following an episode of provoked VTE.
- Do not perform thrombophilia testing in patients following an episode of unprovoked VTE. If a patient with unprovoked VTE and low bleeding risk is planning to stop anticoagulation, test for thrombophilia if test results would change this decision. A negative thrombophilia evaluation is not a sufficient basis to stop anticoagulants following an episode of unprovoked VTE in a patient with low bleeding risk and willingness to continue therapy. Heterozygosity for FVL or PGM does not increase the predicted risk of recurrence after unprovoked VTE to a clinically significant degree.
- Do not test for thrombophilia in asymptomatic family members of patients with VTE or hereditary thrombophilia. As a family history of VTE confers an excess risk of thrombosis, relatives should be counseled regarding use of prophylaxis in high-risk situations.
- Do not test for thrombophilia in asymptomatic family members of patients with VTE or hereditary thrombophilia who are contemplating use of estrogen. If an [individual] is contemplating estrogen use has a first-degree relative with VTE and a known hereditary thrombophilia, test for that thrombophilia if the result would change the decision to use estrogen.
- Do not perform thrombophilia testing at the time of VTE diagnosis or during the initial 3-month course of anticoagulant therapy. When testing for thrombophilias following VTE, use either a 2-stage testing approach or perform testing after a minimum of 3 months of anticoagulant therapy has been completed, and anticoagulants have been held.
- Do not test for thrombophilia in asymptomatic family members of patients with VTE or hereditary thrombophilia who are contemplating pregnancy. If [an individual] contemplating pregnancy has a first-degree relative with VTE and a known hereditary thrombophilia... test for that thrombophilia if the result would change VTE prophylaxis decisions” (Stevens et al., 2016).

### **American College of Cardiology (ACC)**

In 2017, guidance published in the New England Journal of Medicine by Gupta was summarized by Barnes for the American College of Cardiology:

1. “Venous thromboembolism (VTE) affects an estimated 300,000-600,000 patients annually in the United States.
2. The risk of VTE recurrence is best predicted by whether the initial VTE episode was provoked or unprovoked, not the results of inherited thrombophilia testing.

3. Most patients with a provoked VTE have recently undergone surgery, immobility, trauma, or have a concurrent cancer diagnosis. Concurrent use of hormones (e.g., estrogen-containing contraceptive pills) is also frequently considered a provoking factor for VTE development.
4. For patients with a first provoked VTE event, guidelines recommend anticoagulation for only 3 months (not longer). Prolonged anticoagulation is associated with an increased risk of bleeding that outweighs the risk of VTE recurrence for these patients.
5. Patients with an unprovoked VTE (none of the provoking risk factors listed above) require longer anticoagulation due to a higher risk of recurrence that outweighs the risk of bleeding associated with long-term anticoagulation therapy.
6. Thrombophilia testing performed in the setting of an acute clot or ongoing anticoagulation therapy will often result in spurious results (usually false positive). For example, natural anticoagulants (e.g., protein C and S, antithrombin) are consumed during an acute thrombotic event and the levels can be reduced by ongoing anticoagulant therapy.
7. A recent study identified that up to 55% of Medicare patients with provoked VTE had undergone inappropriate thrombophilia testing, associated with significant cost to the healthcare system.
8. While thrombophilia testing rarely impacts management decisions about anticoagulation therapy, it may be beneficial for genetic testing purposes in patients presenting with a first unprovoked VTE at a young age (e.g., <45 years) or at an unusual site.
9. For patients with unprovoked VTE at a young age, VTE at an unusual site, arterial thrombosis, or pregnancy morbidity, testing for antiphospholipid antibodies, JAK2 mutation, and paroxysmal nocturnal hemoglobinuria may be beneficial.
10. There is no role for extensive cancer screening (e.g., computed tomography scanning) in patients with VTE. Only routine, age-appropriate cancer screening is recommended” (G. Barnes, 2017; Gupta et al., 2017).

Again in 2017, key points—inclusive of guiding points—published in the New England Journal of Medicine by Connors were captured by Barnes for the American College of Cardiology:

1. “The majority of patients with venous thromboembolism (VTE) should not be tested for thrombophilia. Data supporting clinical usefulness and benefits are limited or nonexistent.
2. Most patients with inherited thrombophilia can be identified by coagulation experts based on the patient’s personal and family history of VTE. Thrombophilia testing is usually not required.
3. Factors associated with an inherited thrombophilia include VTE at a young age (<40-50 years), a strong family history of VTE, VTE in conjunction with weak provoking factors at a young age, recurrent VTE, and VTE in an unusual site (e.g., cerebral or splanchnic veins).
4. Do not perform thrombophilia testing at the time of a VTE event, as it can be inaccurate (often false positive). Perform testing (when indicated) after completion of initial therapy and if it might change management strategies.
5. Do not perform thrombophilia testing while a patient is receiving anticoagulation. Instead, wait until 2 weeks after discontinuing warfarin, or 2 days for direct oral anticoagulants and heparin.

6. The goal of thrombophilia testing should be to aid decision making regarding future VTE prophylaxis, to guide testing of family members, and to determine the cause in severe or fatal VTE. Test results alone should not be used to decide on the duration of anticoagulation therapy.
7. Most VTE recurrence risk tools do not incorporate thrombophilia test results into their risk stratification schemes.
8. For patients with provoked VTE, even if they have homozygous factor V Leiden, prothrombin gene mutations, or deficiencies of protein S, C, or antithrombin, they do not require lifelong anticoagulation.
9. Currently available thrombophilia tests are insufficient to identify inherited risks of VTE. Therefore, a negative test should not be interpreted as a patient being free of thrombophilia.
10. Testing for the antiphospholipid antibody syndrome may be useful in patients with unprovoked VTE if there is clinical equipoise about extended anticoagulation courses. It can also be useful to determine warfarin versus direct oral anticoagulant therapy” (G. D. Barnes, 2017; Connors, 2017).

### **European Society of Cardiology**

The ESC has published guidelines for the diagnosis and management of acute PE. These guidelines state:

- “D-dimer measurement and clinical prediction rules should be considered to rule out PE during pregnancy or the post-partum period
- Plasma D-dimer measurement, preferably using a highly sensitive assay, is recommended in outpatients/emergency department patients with low or intermediate clinical probability, or those that are PE-unlikely, to reduce the need for unnecessary imaging and irradiation
- A D-dimer test, using an age-adjusted cut-off or adapted to clinical probability, should be considered as an alternative to the fixed cut-off level
- D-dimer measurement is not recommended in patients with high clinical probability, as a normal result does not safely exclude PE, even when using a highly sensitive assay
- Assessment of the RV [right ventricle] by imaging methods or laboratory biomarkers should be considered, even in the presence of a low PESI [Pulmonary Embolism Severity Index] or a negative sPESI [simplified Pulmonary Embolism Severity Index]” (Konstantinides et al., 2019).

In 2021, the ESC Working Group released guidelines on diagnosis and management of acute deep vein thrombosis. These guidelines suggest that “ELISA D-dimer or highly sensitive immunoturbidimetric tests should be measured in ‘unlikely’ clinical probability patients to exclude DVT diagnosis” (Mazzolai et al., 2022).

### **World Health Organization (WHO)**

In the WHO medical eligibility criteria for contraceptive use, known thrombogenic mutations (e.g. factor V Leiden; prothrombin mutation; protein S, protein C, and antithrombin deficiencies) are “a condition which represents an unacceptable health risk if the contraceptive method is used” when considering combined hormonal contraceptives, and the method is “not to be used.” The WHO notes that “among women with thrombogenic mutations, COC users had a 2- to 20-fold

higher risk of thrombosis than non-users.” When considering progestogen-only contraceptives, intrauterine devices, barrier methods, or female surgical sterilization, known thrombogenic mutations are “a condition for which there is no restriction for the use of the contraceptive method” or “the advantages of using the method generally outweigh the theoretical or proven risks.” In all cases, the WHO clarifies that “routine screening is not appropriate because of the rarity of the conditions and the high cost of screening” (WHO, 2015).

### **National Institute for Health and Care Excellence (NICE)**

In the NICE venous thromboembolic disease guidelines, for thrombophilia testing, it is recommended:

- “Do not offer testing for hereditary thrombophilia to people who are continuing anticoagulation treatment.
- “Do not offer thrombophilia testing to people who have had provoked DVT or PE.”
- “Consider testing for antiphospholipid antibodies in people who have had unprovoked DVT or PE if it is planned to stop anticoagulation treatment, but be aware that these tests can be affected by anticoagulants and specialist advice may be needed.”
- “Consider testing for hereditary thrombophilia in people who have had unprovoked DVT or PE and who have a first-degree relative who has had DVT or PE if it is planned to stop anticoagulation treatment, but be aware that these tests can be affected by anticoagulants and specialist advice may be needed.”

“Do not routinely offer thrombophilia testing to first-degree relatives of people with a history of DVT or PE and thrombophilia” (NICE, 2023).

### **American College of Radiology (ACR)**

The ACR has guidelines for suspected pulmonary embolisms (PE). The ARC prefaced that their publication “focuses on the initial evaluation for clinically suspected PE, recognizing that as many as 80% of PE cases are associated with DVT” and that “PE also may occur without detectable DVT.” The guidelines do not mention any laboratory or genetic testing, although some of the imaging recommendations are based on positive or negative D-dimer results (Kirsch et al., 2022).

### **Thrombosis Canada**

Thrombosis Canada released guidelines on the diagnosis of PE (Thrombosis Canada, 2023). They state: “The constellation of symptoms and signs may be suggestive of PE but do not alone have the sensitivity or specificity to rule in or rule out the diagnosis. When the diagnosis of PE is considered, the clinical stability of the patient and associated pre-test probability will dictate the diagnostic approach.” The guidelines further recommend:

- “In patients without hypotension (SBP >90 mmHg), pre-test probability can be assessed by a validated clinical prediction rule such as the Well’s score. In patients who are <50 years of age, with a low pretest probability of PE, further testing (such as d-dimer measurement or diagnostic imaging) is not necessary provided all clinical features/criteria



- in the Pulmonary Embolism Rule-out Criteria (PERC) are present.”
- “In cases with PE unlikely pre-test probability, a negative high sensitivity D-dimer result rules out the diagnosis of PE. However, a positive D-dimer test MUST be followed up with a definitive test to confirm/refute the diagnosis of PE.
  - When a high-sensitive d-dimer assay is used, age-adjusted D-dimer levels can increase the specificity of D-dimer testing without sacrificing sensitivity. In patients over the age of 50, a D-dimer result is considered negative if it is less than the patient age multiplied by 10 (for example, in a 76-year-old, a negative result is less than 760 µg/L). For patients under the age of 50, a D-dimer value less than 500 µg/L remains the cutoff for a negative result.
  - With a high PE pre-test probability (Well’s score > 4.5), there is no role for ordering a D-dimer, as the clinical likelihood of PE remains unacceptably high among those with a negative D-dimer result. Therefore, when the Wells score is 4.5 or greater, one should go directly to imaging to establish the diagnosis” (Thrombosis Canada, 2023).

The Wells Score is a total score of: clinical symptoms and signs of DVT (3 points), previous DVT or PE (1.5 points), immobilization of over three days or surgery within four weeks (1.5 points), heart rate over 100 beats per minute (1.5 points), hemoptysis (1 point), malignancy (1 point), and no alternative diagnosis more likely than PE (3 points). A total score under 4.5 equates to PE unlikely, and a total score of 4.5 or over equates to PE likely (Thrombosis Canada, 2023).

The PE Rule-out Criteria (PERC) for patients with low pretest probability for PE are: age less than 50, initial heart rate of less than 100 beats per minute, initial SaO<sub>2</sub> of over 94% on room air, no unilateral leg swelling, no hemoptysis, no surgery or trauma in the past four weeks, no history of VTE and no estrogen use (Thrombosis Canada, 2023).

## VII. Applicable State and Federal Regulations

**DISCLAIMER:** If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, please visit the applicable state Medicaid website.

### Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

## VIII. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
-----	------------------

81240	F2 (prothrombin, coagulation factor III) (eg, hereditary hypercoagulability) gene analysis, 20210G>A variant
81241	F5 (coagulation factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant
81291	MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)
81400	Molecular pathology procedure, Level 1 (eg, identification of single germline variant [eg, SNP]) by techniques such as restriction enzyme digestion or melt curve analysis.
81479	Unlisted molecular pathology procedure
85300	Clotting inhibitors or anticoagulants; antithrombin III, activity
85301	Clotting inhibitors or anticoagulants; antithrombin III, antigen assay
85302	Clotting inhibitors or anticoagulants; protein C, antigen
85303	Clotting inhibitors or anticoagulants; protein C, activity
85305	Clotting inhibitors or anticoagulants; protein S, total
85306	Clotting inhibitors or anticoagulants; protein S, free
85307	Activated Protein C (APC) resistance assay
0278U	Hematology (genetic thrombosis), genomic sequence analysis of 14 genes, blood, buccal swab, or amniotic fluid Proprietary test: Versiti™ Thrombosis Panel Lab/Manufacturer: Versiti™

Current Procedural Terminology© American Medical Association. All Rights reserved.

*Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.*

## IX. Evidence-based Scientific References

- ACOG. (2013). ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. *Obstet Gynecol*, 122(3), 706-717. <https://doi.org/10.1097/01.AOG.0000433981.36184.4e>
- ACOG. (2018). ACOG Practice Bulletin No. 197 Summary: Inherited Thrombophilias in Pregnancy. *Obstet Gynecol*, 132(1), 249-251. <https://doi.org/10.1097/aog.0000000000002705>
- Algahtani, F. H., & Stuckey, R. (2019). High factor VIII levels and arterial thrombosis: illustrative case and literature review. *Ther Adv Hematol*, 10, 2040620719886685. <https://doi.org/10.1177/2040620719886685>
- ASCLS. (2021). American Society for Clinical Laboratory Science. <https://www.choosingwisely.org/clinician-lists/ascls7-do-not-order-a-homocysteine-assay-as-part-of-the-thrombophilia-work-up/>
- ASCP. (2017). *American Society for Clinical Pathology*. <http://www.choosingwisely.org/clinician-lists/ascp-testing-for-protein-c-protein-s-or-antithrombin-during-active-clotting-event/>
- ASCP. (2019). *American Society of Clinical Pathology*. American Society of Clinical Pathology. <https://www.choosingwisely.org/clinician-lists/ascp-hypercoagulable-workup/>
- ASH. (2013). *ASH - Testing for thromboembolism | Choosing Wisely* <http://www.choosingwisely.org/clinician-lists/american-society-hematology-testing-for-thrombophilia-in-adults/>

- Bank, I., Libourel, E. J., Middeldorp, S., Hamulyak, K., van Pampus, E. C., Koopman, M. M., Prins, M. H., van der Meer, J., & Buller, H. R. (2005). Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. *J Thromb Haemost*, 3(1), 79-84. <https://doi.org/10.1111/j.1538-7836.2004.01033.x>
- Barnes, G. (2017, 06/05/2017). *Thrombophilia Testing for Provoked VTE*. American College of Cardiology. Retrieved 02/13/2019 from <https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/06/05/12/46/thrombophilia-testing-in-provoked-venous-thromboembolism>
- Barnes, G. D. (2017). *Thrombophilia Testing and Venous Thrombosis*. American College of Cardiology. <https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/10/20/11/18/thrombophilia-testing-and-venous-thrombosis>.
- Bartholomew, J. R. (2017). Update on the management of venous thromboembolism. *Cleve Clin J Med*, 84(12 Suppl 3), 39-46. <https://doi.org/10.3949/ccjm.84.s3.04>
- Bashford, M. T., Hickey, S. E., Curry, C. J., Toriello, H. V., American College of Medical, G., Genomics Professional, P., & Guidelines, C. (2020). Addendum: ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. *Genetics in Medicine*, 22(12), 2125-2125. <https://doi.org/10.1038/s41436-020-0843-0>
- Bauer, K. (2023a, 03/30/2023). *Factor V Leiden and activated protein C resistance*. <https://www.uptodate.com/contents/factor-v-leiden-and-activated-protein-c-resistance>
- Bauer, K. (2023b, 10/18/2023). *Protein C deficiency*. <https://www.uptodate.com/contents/protein-c-deficiency>
- Bauer, K. (2023c, 02/18/2023). *Prothrombin G20210A mutation*. <https://www.uptodate.com/contents/prothrombin-g20210a-mutation>
- Bauer, K. (2024a, 03/8/2024). *Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity*. <https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-deep-vein-thrombosis-of-the-lower-extremity>
- Bauer, K. (2024b, 03/05/2024). *Protein S deficiency*. <https://www.uptodate.com/contents/protein-s-deficiency>
- Bauer, K., & Lip, G. (2023, 05/18/2023). *Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors*. <https://www.uptodate.com/contents/evaluating-adult-patients-with-established-venous-thromboembolism-for-acquired-and-inherited-risk-factors>
- Bauer, K., & Lip, G. (2024, 06/18/2024). *Overview of the causes of venous thrombosis*. <https://www.uptodate.com/contents/overview-of-the-causes-of-venous-thrombosis>
- Byrnes, J. R., & Wolberg, A. S. (2017). Red blood cells in thrombosis. *Blood*, 130(16), 1795-1799. <https://doi.org/10.1182/blood-2017-03-745349>
- Carroll, B. J., & Piazza, G. (2018). Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test? *Vasc Med*, 23(4), 388-399. <https://doi.org/10.1177/1358863x18755927>
- Chiasakul, T., De Jesus, E., Tong, J., Chen, Y., Crowther, M., Garcia, D., Chai-Adisaksopha, C., Messe, S. R., & Cuker, A. (2019). Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. *J Am Heart Assoc*, 8(19), e012877. <https://doi.org/10.1161/jaha.119.012877>
- Connors, J. M. (2017). Thrombophilia Testing and Venous Thrombosis. In *N Engl J Med* (Vol. 377, pp. 2298). <https://doi.org/10.1056/NEJMc1713797>

- Crous-Bou, M., Harrington, L. B., & Kabrhel, C. (2016). Environmental and genetic risk factors associated with venous thromboembolism. *Semin Thromb Hemost*, 42(8), 808-820. <https://doi.org/10.1055/s-0036-1592333>
- Curtis, C., Mineyko, A., Massicotte, P., Leaker, M., Jiang, X. Y., Floer, A., & Kirton, A. (2017). Thrombophilia risk is not increased in children after perinatal stroke. *Blood*, 129(20), 2793-2800. <https://doi.org/10.1182/blood-2016-11-750893>
- de Moerloose, P., Reber, G., Perrier, A., Perneger, T., & Bounameaux, H. (2000). Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. *Br J Haematol*, 110(1), 125-129. <https://doi.org/10.1046/j.1365-2141.2000.02039.x>
- EGAPP. (2011). Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. *Genet Med*, 13(1), 67-76. <https://doi.org/10.1097/GIM.0b013e3181f8e46f>
- Ferriero, D. M., Fullerton, H. J., Bernard, T. J., Billingham, L., Daniels, S. R., DeBaun, M. R., deVeber, G., Ichord, R. N., Jordan, L. C., Massicotte, P., Meldau, J., Roach, E. S., Smith, E. R., & Nursing, A. H. A. S. C. a. C. o. C. a. S. (2019). Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. *Stroke*, 50(3). <https://doi.org/10.1161/str.0000000000000183>
- Gupta, A., Sarode, R., & Nagalla, S. (2017). Thrombophilia Testing in Provoked Venous Thromboembolism: A Teachable Moment. *JAMA Internal Medicine*, 177(8), 1195-1196. <https://doi.org/10.1001/jamainternmed.2017.1815>
- Herrmann, J. (2018). *Clinical Cardio-Oncology*. Elsevier. <https://doi.org/10.1016/C2015-0-01414-9>
- Hickey, S. E., Curry, C. J., & Toriello, H. V. (2013). ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. *Genet Med*, 15(2), 153-156. <https://doi.org/10.1038/gim.2012.165>
- Kirsch, J., Wu, C. C., Bolen, M. A., Henry, T. S., Rajiah, P. S., Brown, R. K. J., Galizia, M. S., Lee, E., Rajesh, F., Raptis, C. A., Rybicki, F. J., Sams, C. M., Verde, F., Villines, T. C., Wolf, S. J., Yu, J., Donnelly, E. F., & Abbara, S. (2022). ACR Appropriateness Criteria® Suspected Pulmonary Embolism: 2022 Update. *J Am Coll Radiol*, 19(11s), S488-s501. <https://doi.org/10.1016/j.jacr.2022.09.014>
- Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockcroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., Lennon, O., Meschia, J. F., Nguyen, T. N., Pollak, P. M., Santangeli, P., Sharrief, A. Z., Smith, S. C., Jr., Turan, T. N., & Williams, L. S. (2021). 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. *Stroke*, 52(7), e364-e467. <https://doi.org/10.1161/str.0000000000000375>
- Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G. J., Harjola, V. P., Huisman, M. V., Humbert, M., Jennings, C. S., Jimenez, D., Kucher, N., Lang, I. M., Lankeit, M., Lorusso, R., Mazzolai, L., Meneveau, N., Ainle, F. N., Prandoni, P., Pruszczyk, P., . . . Zamorano, J. L. (2019). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *Eur Respir J*, 54(3). <https://doi.org/10.1183/13993003.01647-2019>

- Kujovich, J. L. (2011). Factor V Leiden thrombophilia. *Genet Med*, 13(1), 1-16.  
<https://doi.org/10.1097/GIM.0b013e3181faa0f2>
- Kujovich, J. L. (2018). Factor V Leiden Thrombophilia. In M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, & A. Amemiya (Eds.), *GeneReviews((R))*. University of Washington, Seattle. <https://www.ncbi.nlm.nih.gov/books/NBK1368/>
- Lee, E. J., Dykas, D. J., Leavitt, A. D., Camire, R. M., Ebberink, E., García de Frutos, P., Gnanasambandan, K., Gu, S. X., Huntington, J. A., Lentz, S. R., Mertens, K., Parish, C. R., Rezaie, A. R., Sayeski, P. P., Cromwell, C., Bar, N., Halene, S., Neparidze, N., Parker, T. L., . . . Lee, A. I. (2017). Whole-exome sequencing in evaluation of patients with venous thromboembolism. *Blood Adv*, 1(16), 1224-1237.  
<https://doi.org/10.1182/bloodadvances.2017005249>
- Lehman, L. L., Beaute, J., Kapur, K., Danehy, A. R., Bernson-Leung, M. E., Malkin, H., Rivkin, M. J., & Trenor, C. C. (2017). Workup for Perinatal Stroke Does Not Predict Recurrence. *Stroke*, 48(8), 2078-2083. <https://doi.org/10.1161/STROKEAHA.117.017356>
- Leung, A. N., Bull, T. M., Jaeschke, R., Lockwood, C. J., Boisselle, P. M., Hurwitz, L. M., James, A. H., McCullough, L. B., Menda, Y., Paidas, M. J., Royal, H. D., Tapson, V. F., Winer-Muram, H. T., Chervenak, F. A., Cody, D. D., McNitt-Gray, M. F., Stave, C. D., & Tuttle, B. D. (2011). An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy. *Am J Respir Crit Care Med*, 184(10), 1200-1208. <https://doi.org/10.1164/rccm.201108-1575ST>
- Lim, W., Le Gal, G., Bates, S. M., Righini, M., Haramati, L. B., Lang, E., Kline, J. A., Chasteen, S., Snyder, M., Patel, P., Bhatt, M., Patel, P., Braun, C., Begum, H., Wiercioch, W., Schünemann, H. J., & Mustafa, R. A. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. *Blood Adv*, 2(22), 3226.  
<https://doi.org/10.1182/bloodadvances.2018024828>
- Linkins, L. A., & Takach Lapner, S. (2017). Review of D-dimer testing: Good, Bad, and Ugly. *Int J Lab Hematol*, 39 Suppl 1, 98-103. <https://doi.org/10.1111/ijlh.12665>
- Mäkelburg, A. B., Veeger, N. J., Middeldorp, S., Hamulyák, K., Prins, M. H., Büller, H. R., & Lijfering, W. M. (2010). Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. *Haematologica*, 95(6), 1030-1033. <https://doi.org/10.3324/haematol.2009.017061>
- Mazzolai, L., Ageno, W., Alatri, A., Bauersachs, R., Becattini, C., Brodmann, M., Emmerich, J., Konstantinides, S., Meyer, G., Middeldorp, S., Monreal, M., Righini, M., & Aboyans, V. (2022). Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. *European Journal of Preventive Cardiology*.  
<https://doi.org/10.1093/eurjpc/zwab088>
- Middeldorp, S., Nieuwlaet, R., Baumann Kreuziger, L., Coppens, M., Houghton, D., James, A. H., Lang, E., Moll, S., Myers, T., Bhatt, M., Chai-Adisaksopha, C., Colunga-Lozano, L. E., Karam, S. G., Zhang, Y., Wiercioch, W., Schünemann, H. J., & Iorio, A. (2023). American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. *Blood Adv*, 7(22), 7101-7138.  
<https://doi.org/10.1182/bloodadvances.2023010177>



- Middeldrop, S. (2023, May 30 2023). *Lab Interpretation: Positive factor V Leiden or abnormal activated protein C resistance in adults*. <https://www.uptodate.com/contents/factor-v-leiden-and-activated-protein-c-resistance>
- Murphy, C. H., & Sabath, D. E. (2019). Comparison of Phenotypic Activated Protein C Resistance Testing With a Genetic Assay for Factor V Leiden. *Am J Clin Pathol*, 151(3), 302-305. <https://doi.org/10.1093/ajcp/aqy142>
- NATF. (2019). *Genetic Risk Factors for Blood Clots and the Role of Genetic Testing*. <https://natfonline.org/2019/01/genetic-risk-factors-blood-clots-role-genetic-testing/>
- NICE. (2023). Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. <https://www.nice.org.uk/guidance/ng158/chapter/Recommendations#thrombophilia-testing>
- Onda, S., Furukawa, K., Haruki, K., Hamura, R., Shirai, Y., Yasuda, J., Shiozaki, H., Gocho, T., Shiba, H., & Ikegami, T. (2021). d-dimer-based screening for early diagnosis of venous thromboembolism after hepatectomy. *Langenbeck's Archives of Surgery*, 406(3), 883-892. <https://doi.org/10.1007/s00423-020-02058-9>
- Ordieres-Ortega, L., Demelo-Rodríguez, P., Galeano-Valle, F., Kremers, B. M. M., ten Cate-Hoek, A. J., & ten Cate, H. (2020). Predictive value of D-dimer testing for the diagnosis of venous thrombosis in unusual locations: A systematic review. *Thrombosis Research*, 189, 5-12. <https://doi.org/10.1016/j.thromres.2020.02.009>
- Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., Thurston, C., Vedantham, S., Verhamme, P., Witt, D. M., D. Florez, I., Izcovich, A., Nieuwlaat, R., Ross, S., J. Schünemann, H., . . . Zhang, Y. (2020). American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. *Blood Adv*, 4(19), 4693-4738. <https://doi.org/10.1182/bloodadvances.2020001830>
- Previtali, E., Bucciarelli, P., Passamonti, S. M., & Martinelli, I. (2011). Risk factors for venous and arterial thrombosis. *Blood Transfus*, 9(2), 120-138. <https://doi.org/10.2450/2010.0066-10>
- Raffini, L., Mahoney, D. H., & Armsby, C. (2023). Thrombophilia testing in children and adolescents. *UpToDate*. <https://www.uptodate.com/contents/thrombophilia-testing-in-children-and-adolescents>
- Segal, J. B., Brotman, D. J., Emadi, A., Necochea, A. J., Samal, L., Wilson, L. M., Crim, M. T., & Bass, E. B. (2009). Outcomes of genetic testing in adults with a history of venous thromboembolism. *Evid Rep Technol Assess (Full Rep)*(180), 1-162. <https://pubmed.ncbi.nlm.nih.gov/20629476/>
- SIGN. (2014). *Prevention and management of venous thromboembolism* <https://www.sign.ac.uk/media/1060/sign122.pdf>
- Stevens, S. M., Woller, S. C., Bauer, K. A., Kasthuri, R., Cushman, M., Streiff, M., Lim, W., & Douketis, J. D. (2016). Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. *J Thromb Thrombolysis*, 41, 154-164. <https://doi.org/10.1007/s11239-015-1316-1>
- SVM. (2013, 02/21/2013). *Don't do work up for clotting disorder (order hypercoagulable testing) for patients who develop first episode of deep vein thrombosis (DVT) in the setting of a known cause*. ABIM. <https://www.aafp.org/pubs/afp/collections/choosing-wisely/32.html>
- Thompson, B. T., Kabrhel, Christopher. (2023, 12/2023). *Overview of acute pulmonary embolism in adults*. <https://www.uptodate.com/contents/overview-of-acute-pulmonary-embolism-in-adults>



- Thrombosis Canada. (2023). Pulmonary Embolism (PE): Diagnosis.  
[https://thrombosiscanada.ca/hcp/practice/clinical\\_guides?language=en-ca&guideID=PULMONARYEMBOLISMDIAGNOSISANDM](https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=PULMONARYEMBOLISMDIAGNOSISANDM)
- WHO. (2015). Medical eligibility criteria for contraceptive use.  
<https://www.who.int/publications/i/item/9789241549158>
- Zhang, S., Taylor, A. K., Huang, X., Luo, B., Spector, E. B., Fang, P., & Richards, C. S. (2018). Venous thromboembolism laboratory testing (factor V Leiden and factor II c.\*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*, 20(12), 1489-1498. <https://doi.org/10.1038/s41436-018-0322-z>

## X. Review/Revision History

Effective Date	Summary
01/01/2025	<p>Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review necessitated the following changes in coverage criteria:</p> <p>Added “or pulmonary embolism (PE).” to CC1a</p> <p>New CC3: “3) For individuals with a first-degree relative (see Note 2) with a known Factor V Leiden or prothrombin gene G20210A mutation, genetic testing for the known familial mutation MEETS COVERAGE CRITERIA in any of the following situations:</p> <ul style="list-style-type: none"> <li>a) For individuals who are considering the use of oral contraceptives.</li> <li>b) For individuals who were assigned female at birth and who are considering hormone replacement therapy.”</li> </ul> <p>CC1.e. and CC12 edited for clarity and consistency.</p> <p>Updated code description for CPT code 0278U (effective date 10/1/2023)</p>
12/01/2024	Initial Policy Implementation